tetano
Editor, Senior Moderator
Artif Cells Nanomed Biotechnol. 2018 Apr 24:1-7. doi: 10.1080/21691401.2018.1464460. [Epub ahead of print]
[h=1]Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles.[/h] Mosafer J[SUP]1,[/SUP][SUP]2[/SUP], Badiee A[SUP]2,[/SUP][SUP]3[/SUP], Mohammadamini Z[SUP]3[/SUP], Komeilinezhad A[SUP]3[/SUP], Tafaghodi M[SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Chitosan-coated ISCOMATRIX nanoparticles co-administrated with PR8 influenza virus were successfully developed via a lipid film hydration method to evaluate their in vivo immuniadjuvant potential in immunization against influenza. The prepared ISCOMATRIX (ISC) and chitosan-coated ISCOMATRIX (ISC-CIT) showed a particle size of 171 and 233 nm with a zeta potential of -9.47 and +5.65, respectively. Furthermore, ISC-CIT formulations were co-administered with PR8 antigen (PR8-ISC-CIT) and their immunogenicity was investigated after intranasal and intramuscular immunization of BALBc/mice. The PR8-ISC formulation elicited more IFN-γ after intranasal or intramuscular administration compared with PR8-ISC-CIT formulation. In contrast, although PR8-ISC-CIT formulation administered by intranasal route secreted more IFN-γ, it significantly decreased the IgG2a/IgG1 ratio and a less immune response was induced. Altogether, the ISC-adjuvanted influenza PR8 antigen could be considered as a powerful intramuscular antigen delivery system for producing a variety of prophylactic and therapeutic vaccines.
[h=4]KEYWORDS:[/h] ISCOMATRIX; Immune response; PR8 influenza virus; chitosan-coated ISCOMATRIX; nasal immunization
PMID: 29688038 DOI: 10.1080/21691401.2018.1464460
[h=1]Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles.[/h] Mosafer J[SUP]1,[/SUP][SUP]2[/SUP], Badiee A[SUP]2,[/SUP][SUP]3[/SUP], Mohammadamini Z[SUP]3[/SUP], Komeilinezhad A[SUP]3[/SUP], Tafaghodi M[SUP]2,[/SUP][SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Chitosan-coated ISCOMATRIX nanoparticles co-administrated with PR8 influenza virus were successfully developed via a lipid film hydration method to evaluate their in vivo immuniadjuvant potential in immunization against influenza. The prepared ISCOMATRIX (ISC) and chitosan-coated ISCOMATRIX (ISC-CIT) showed a particle size of 171 and 233 nm with a zeta potential of -9.47 and +5.65, respectively. Furthermore, ISC-CIT formulations were co-administered with PR8 antigen (PR8-ISC-CIT) and their immunogenicity was investigated after intranasal and intramuscular immunization of BALBc/mice. The PR8-ISC formulation elicited more IFN-γ after intranasal or intramuscular administration compared with PR8-ISC-CIT formulation. In contrast, although PR8-ISC-CIT formulation administered by intranasal route secreted more IFN-γ, it significantly decreased the IgG2a/IgG1 ratio and a less immune response was induced. Altogether, the ISC-adjuvanted influenza PR8 antigen could be considered as a powerful intramuscular antigen delivery system for producing a variety of prophylactic and therapeutic vaccines.
[h=4]KEYWORDS:[/h] ISCOMATRIX; Immune response; PR8 influenza virus; chitosan-coated ISCOMATRIX; nasal immunization
PMID: 29688038 DOI: 10.1080/21691401.2018.1464460